Jaguar Health obtains a patent for its plant-based drug crofelemer in Hong Kong for treating short bowel syndrome and related conditions.

Jaguar Health announces a new patent from Hong Kong's Intellectual Property Department for Napo Pharmaceuticals, enhancing IP protection for crofelemer, a novel plant-based prescription drug treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea linked to small intestine resection or gallbladder removal. This patent adds to the 230 patents for crofelemer, reinforcing Jaguar's position in the treatment market for SBS and MVID. Independent investigator-initiated proof-of-concept studies for crofelemer in SBS and microvillus inclusion disease (MVID) are being supported by Jaguar in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025.

August 19, 2024
5 Articles